Two recently published studies have independently demonstrated that pre-treatment status of systemic CD4 immunity is a critical factor for determining the clinical outcome of PD-L1/PD-1 blockade therapy in NSCLC patients. Here, CD274 is linked to non-small cell lung carcinoma.